Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely

 
• By Alaric DeArment
Doctor with Mammography - Image
Keytruda unveils EFS data for Keytruda in triple-negative breast cancer and seeks FDA approval • Source: Shutterstock

More from Immuno-oncology

More from Anticancer